Clinical Evidence
Atopic Dermatitis & Eczema-Prone Skin
Clinical Study Overview
XTRIMOIST-AD Moisturizing Lotion was evaluated in a randomized, single-blind clinical study conducted on participants with mild to moderate Atopic Dermatitis/Eczema.
Topical steroid treatment
alone
Topical Steroid treatment + XTRIMOIST AD Moisturising Lotion
Study Duration
21 days
Study Design
Randomized, evaluator-blinded clinical study
Key Clinical Findings
Significant Reduction in Eczema Severity
Participants using XTRIMOIST-AD Moisturizing Lotion alongside topical steroid therapy showed:
Results After 21 Days:
- 30% reduction in EASI score
- Superior improvement compared to steroid treatment alone
(EASI = Eczema Area and Severity Index, a standard clinical measurement for eczema severity.)
Improved Skin
Hydration
Clinical instrumentation showed significantly improved skin hydration levels in participants using XTRIMOIST-AD.
Results After 21 Days:
- Up to 104% increase in skin hydration
- Significantly better hydration compared to steroid-only treatment
Hydration was measured using MoistureMeter SC, an established scientific device used to assess skin moisture levels.
Strengthened Skin Barrier Function
Participants using XTRIMOIST-AD demonstrated a significant reduction in Trans Epidermal Water Loss (TEWL) a key indicator of skin barrier damage.
Results After 21 Days:
- 30.8% reduction in TEWL
- Better barrier protection compared to steroid-only therapy
Significant Relief from Itching
Participants reported substantial reduction in itching symptoms.
Results After 21 Days:
- 82% reduction in itching scores
- Significantly greater improvement compared to steroid-only treatment
Participant Satisfaction After 21 days of use:
soft and smooth
had reduced
overall
noticeably more hydrated
Safety & Tolerance
throughout the study.
Clinical Safety Findings:
- No adverse events reported
- No irritation, burning, tingling, or pricking sensations observed
Quality of Life Improvement
- Skin comfort
- Daily activities
- Social confidence
- Work and lifestyle comfort
The combination of XTRIMOIST-AD with topical therapy showed meaningful improvement in overall skin-related quality of life.
Conclusion
- Up to 104% increase in skin hydration
- 30.8% reduction in TEWL after 21 days
- 82% reduction in itching scores after 21 days
- 100% Agreed Their Skin Felt Soft & Smooth
- Overall eczema symptom management
Clinical evaluation demonstrated that XTRIMOIST-AD Moisturizing Lotion, when used alongside topical steroid therapy, provided superior improvement compared to topical steroid therapy alone.